Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Performance of a Multifocal Contact Lens - Presbyopia Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02450747
Recruitment Status : Completed
First Posted : May 21, 2015
Results First Posted : January 12, 2017
Last Update Posted : June 19, 2018
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Vision Care, Inc.

Brief Summary:
This is a four week study to evaluate the performance of a multifocal contact lens in habitual wearers of silicone hydrogel multifocal contact lenses.

Condition or disease Intervention/treatment Phase
Presbyopia Device: etafilcon A MULTIFOCAL Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : April 2015
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Wear

Arm Intervention/treatment
Experimental: Multifocal Test Contact Lens
Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
Device: etafilcon A MULTIFOCAL
Subjects will wear the test lens for four weeks.




Primary Outcome Measures :
  1. The Total Grade of Conjunctival Hyperemia [ Time Frame: Baseline to 4-Week Follow-up ]
    Hyperemia (Redness) was assessed using two different parts of the eye, the Bulbar and the Limbal. Hypemeria was measured using the Efron Scale in 0.5 step units. Grade 0= No Findings, Grade 1= Slight, Grade 2= Mild , Grade 3= Moderate and Grade 4 = severe. Hypermia was assessed in four regions of the eye (Inferior, Nasal, Temporal and Superior). The total grade of Conjunctival Hypermia across all regions and grades is reported. The total grade can range from 0 to 8. Where a higher grade implies worsening conjunctival hypermia

  2. Upper Lid Margin Staining Score [ Time Frame: Baseline to 4-Week Follow-up ]
    Upper Lid Margin Staining was assessed using Fluorescein Staining and was measured on the Graded Scale is Grade 0: No Staining is present, Grade 1= 1% to 25% Stains, Grade 2= 26% to 50% Stains, Grade 3= 51% to 75% Stains, Grade 4 76% to 100% Stains. The percentage of eyes with upper lid margin staining for each Grade is reported.

  3. Average Corneal Staining Area Grade [ Time Frame: Baseline to 4- Week Follow-up ]
    Corneal staining Area Grade was assessed in throughout five (5) regions in the eye (Central, Nasal, Temporal, Inferior, Superior). Corneal Staining was Graded using the Efron scale from 0 to 4 in 0.1 unit steps and converted to a percentage of region that was stained. The average percent of region that was stained was calculated and reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adult males or females age 40 to 70 and has full legal capacity to volunteer.
  2. The subject is a current spherical silicone hydrogel multifocal (SiHy) contact lens wearer (defined as a minimum of 2 days per week for at least 6 hours of Daily Wear contact lenses, for a minimum of one month prior to the study) and willing to wear the study lenses on a daily basis (defined as a minimum of 6 hours of wear per day) for the duration of the study.
  3. The subject must own a pair of wearable spectacles to wear when they cannot wear the study lenses.
  4. The subject's optimal vertexed spherical equivalent distance correction must be between +3.50 and -5.50 Diopters (D) (inclusive) in both eyes.
  5. Subjective refraction cylinder power must be less than or equal to 0.75 D in both eyes.
  6. Requires a reading addition of +0.75 D to +2.50 D in each eye.
  7. The subject must have distance and near visual acuity best correctable to logMAR 0.1 (20/25) or better at both distance and near with subjective refraction for each eye.
  8. The subject must read and sign the Informed Consent form.
  9. The subject must appear able and willing to adhere the instructions set forth in this clinical protocol.

Exclusion Criteria:

  1. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
  2. Participant in unrelated research clinical trial within 30 days prior to enrollment;
  3. Known to have any infectious disease (e.g.hepatitis, tuberculosis) or a contagious immunosuppressive disease.
  4. Women who are pregnant or lactating or planning a pregnancy at the time of enrollment;
  5. Ocular or systemic allergies or disease which might interfere with contact lens wear;
  6. Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes.
  7. Systemic disease or use of medication which might interfere with contact lens wear;
  8. Any corneal distortion;
  9. Has any known active* ocular disease and/or infection;
  10. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; and only uses rewetting drops on an occasional basis( greater than 2 times per week).
  11. Is a habitual monovision contact lens wearer wearing contact lenses on extended wear basis or for the past 6 months;
  12. Diagnosed with Diabetes;
  13. Is aphakic; or Has entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions.
  14. Has undergone refractive error surgery;
  15. Has amblyopia or strabismus;
  16. Has anisometropia >2 D between both eyes;
  17. Has a known sensitivity to the diagnostic pharmaceuticals to be used in the study;
  18. Any grade 3.0 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear;
  19. Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02450747


Locations
Layout table for location information
Canada, Ontario
Waterloo, Ontario, Canada, N2L 3G1
Sponsors and Collaborators
Johnson & Johnson Vision Care, Inc.

Layout table for additonal information
Responsible Party: Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier: NCT02450747     History of Changes
Other Study ID Numbers: CR-5692
First Posted: May 21, 2015    Key Record Dates
Results First Posted: January 12, 2017
Last Update Posted: June 19, 2018
Last Verified: November 2016
Keywords provided by Johnson & Johnson Vision Care, Inc.:
Visual Acuity
Additional relevant MeSH terms:
Layout table for MeSH terms
Presbyopia
Refractive Errors
Eye Diseases